Altria Group reported robust financial results for 2024, with net earnings increasing 38.5% to $11.3 billion and diluted EPS rising 43.1% to $6.54. The company recorded a $2.7 billion pre-tax gain from assigning IQOS System commercialization rights to PMI and received favorable tax benefits of $969 million. Net revenues decreased 1.9% to $24.0 billion, primarily due to lower smokeable products volume.The smokeable products segment saw domestic cigarette shipment volume decline 10.2%, while Marlboro's retail share reached 41.7%. The oral tobacco products segment recorded a non-cash impairment charge of $354 million for the Skoal trademark, though on! oral nicotine pouches showed continued growth. NJOY's share of the pod-based e-vapor category reached 6.4% in Q4 2024.The company maintained strong shareholder returns, increasing its quarterly dividend by 4.1% to $1.02 per share and completing a $3.4 billion share repurchase program. Altria also announced its Optimize & Accelerate initiative to enhance operational efficiency, expecting at least $600 million in cumulative cost savings over five years. The company faces challenges from illicit e-vapor products and ongoing patent litigation regarding NJOY ACE.

Altria Group reported robust financial results for 2024, with net earnings increasing 38.5% to $11.3 billion and diluted EPS rising 43.1% to $6.54. The company recorded a $2.7 billion pre-tax gain from assigning IQOS System commercialization rights to PMI and received favorable tax benefits of $969 million. Net revenues decreased 1.9% to $24.0 billion, primarily due to lower smokeable products volume.The smokeable products segment saw domestic cigarette shipment volume decline 10.2%, while Marlboro's retail share reached 41.7%. The oral tobacco products segment recorded a non-cash impairment charge of $354 million for the Skoal trademark, though on! oral nicotine pouches showed continued growth. NJOY's share of the pod-based e-vapor category reached 6.4% in Q4 2024.The company maintained strong shareholder returns, increasing its quarterly dividend by 4.1% to $1.02 per share and completing a $3.4 billion share repurchase program. Altria also announced its Optimize & Accelerate initiative to enhance operational efficiency, expecting at least $600 million in cumulative cost savings over five years. The company faces challenges from illicit e-vapor products and ongoing patent litigation regarding NJOY ACE.